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    On the assumption that CSCs are primarily responsible for tumour 
recurrence and therapy resistance future studies (Fig. 7).  
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The theory of Cancer Stem Cells (CSCs) has been proposed for a long time ago, nevertheless demonstration of their existence has only occurred within the last decade. Regarding CSCs are tumour cells 
with properties that are similar to those described for adult stem cells: long-term self-renewal and ability to give rise to one or more differentiated cell linages. The potential significance of CSCs in 
cancer biology has been demonstrated by several studies showing contributions to therapeutic resistance, angiogenesis, and tumor recurrence. 
 
Moreover Glioblastoma (GBM), a WHO-defined grade IV astrocytoma, is the most common and lethal type of primary brain tumours in adults. Despite recent therapeutic advances in other cancers, GBM 
treatment remains essentially palliative and patients median survival is dismal. Within GBM, CSCs referred to as Glioblastoma Stem Cells (GSCs), have the ability to self-renew, differentiate into distinct 
lineages within the tumour, and initiate tumour xenografts in immunocompromised mice. Furthermore GSCs are a tumour cell subset displaying radiotherapy and chemotherapy resistant and likely 
contribute to rapid tumour recurrence. Thereby molecular targeting of GSCs may directly improve current therapies efficacy . 
    z 
Theoretical framework  
 Summarize current state of knowledge about CSCs, focusing on GSCs 
and their role on GBM therapeutic resistance. 
 Create a disclosure tool based on bibliographic review.  
 Design a website aimed to neuro-oncology nurses and residents, and 
to medicine students.  
CSCs are primarily responsible 
for tumour recurrence and 
therapy resistance 
Future studies should focus on 
developing strategies for deplete 
these cells. 
Drugs could impair CSC self-
renewal, induce their specific cell 
death, induce their differentiation 
or target their niche (Figure 4).  
Figure 4. Strategies for deplete CSCs. Image from: Beck 
B, et al. Nat Rev Cancer. 2013. 
Search on Pubmed database using terms such as: glioblastoma, cancer 
stem cells, glioblastoma stem cells, chemoresistance, radioresistance.  
Original and review articles were selected according to publication year 
and journal impact factor. 
 
Previous to website construction it was performed an online survey to 19 
subjects (9 neuro-oncology nurses, 5 neuro-oncology residents, and 5 
medicine students) using the follow website www.e-encuestas.com. 
 
Ultimately website was constructed through online platform 
www.wordpress.com.   
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GBM 
European and 
North America 
incidence:  
3-4/100,000 
person-years 
Treated 
patients 
median overall 
survival: 12-
15 months 
Affects adults 
preferentially 
(peak 
incidence of 
45-60 years) 
Males have 
slight 
preponderance 
over females 
(male/female 
ratio of 3:2) 
Mortality main cause in 
patients with GBM is tumour 
reoccurrence, which is 
attributed to treatment-
resistant CSCs within and 
surrounding primary tumour.  
GSCs 
GSCs may result from genetic 
and epigenetic mutations in 
neural stem/progenitor cells or 
from differentiated cells such as 
astrocytes after a series of 
mutations or an epigenetic 
reprogram.  
GSCs share similar properties 
with normal neural stem cells 
(NSCs) including enhanced 
potentials for proliferation, 
angiogenesis, invasion and 
modulating immune responses.  
Some important stem cell 
transcription factors 
involved in regulating normal 
stem cells (such as Sox2, Oct4, 
Nanog, c-Myc, Olig2 and Bmi1) 
are also required for the 
maintenance of a GSC phenotype. 
GSCs existence has 
been demonstrated by 
two types of assays 
Assessing sphere-
forming efficiency in 
non-adherent culture 
conditions  
Carrying out tumour-
initiating assays in 
immunocompromised 
mice  
Clonogenic assays 
 In vitro 
Tumorigenic assays 
In vivo  
GSCs niche 
GSCs resistance 
mechanisms 
Like normal adult stem 
cells, GSCs also may 
exist in a specialized 
microenvironment, a 
stem cell niche. Several 
studies have shown 
that GSCs may be 
within two types of 
niches. 
GSCs are located in close contact with endothelial 
cells (ECs) 113+, which secrete soluble factors for 
maintain the self-renewal and undifferentiated 
phenotype of GSCs (Figure 1).  
Perivascular niche 
GSCs may exist within hypoxic niches to maintain lower 
levels of reactive oxygen species (ROS) and to remain out 
of reach of chemotherapy promoting their survival and 
phenotype. 
Figure 1. GBM frozen section was immuno-
stained with anti-L1CAM antibody for GSCs and 
anti-CD31 antibody for ECs of blood vessel, and 
counterstained with DAPI for DNA. Image from: 
Bao S, et al. Cancer Res. 2006. 
Current therapy for 
newly diagnosed GBM 
includes maximal 
tumour bulk resection 
followed by 
radiotherapy and 
adjuvant 
chemotherapy with 
temozolomide (TMZ) 
Hypoxic niche 
GSCs enhance DNA damage response  
(DDR) as a result of DNA injury induced 
by radiation. DDR was measured by the 
activating phosphorylation of several 
critical checkpoint proteins (ATM, Rad17, 
Chk2 and Chk1).  
Radioresistance 
Figure 2. In GCSs DDCR is 
potentiated by up-regulation of 
Nijmegen-breakage syndrome-
1 (NBS-1) protein, a critical 
component of the MRE11-
RAD50-NBS1 (MRN) complex 
that activates the ataxia 
telangiectasia mutated (ATM) 
kinase. Image from: Alison MR, 
et al. Cancer Treat Rev. 2012. 
As mentioned above before constructing website 
it was performed online surveys with the 
selected population sample. Four questions were 
formulated in the survey, each with only one 
option to response (overall results may be 
consulted on memory project). 
 
Information gathered through the extensive 
bibliographic review was reflected on website 
adapting the concepts to population knowledge. 
Website design was performed according to 
results of previous survey. Below it is provide 
the website link 
https://glioblastomastemcells.wordpress.com/   
(Fig. 3).  
 Consistent with the idea that inducing CSC differentiation might be therapeutically 
beneficial, it has been shown that bone morphogenetic protein 4 (BMP-4) induces 
the differentiation of GSCs and inhibits tumour growth in vivo when BMP4-coated 
beads were orthotopically transplanted together with GSCs into immunodeficient 
mice. 
 MicroRNAs (miRs) can also target the Notch pathway in GBM, miR-34a targets 
Notch1 and Notch2 mRNAs, resulting in GSC differentiation.  
 One of the main goals of future studies in GBM would be to develop therapies 
aimed at decreasing radioresistance and chemoresistance of GSCs. Therefore 
radio-chemoresistance molecular mechanisms should continue to be investigated. 
  it was determined that CD133+ GSCs are primarily radioresistant, and that these 
cells can be sensitized by inhibition of Chk1 and Chk2. 
Figure 3. Snapshot of website home. 
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GSCs express high levels of the repair enzyme O6-methylguanine-
DNAmethyltransferase (MGMT), removing DNA adducts induced by TMZ. 
Furthermore GSCs increased expression of drug transporters including the 
adenosine triphosphate-binding cassette (ABC) transporters that pump out 
chemotherapeutic agents.  
Chemoresistance 
